Bleakley Financial Group LLC Raises Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Bleakley Financial Group LLC boosted its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 24.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,215 shares of the biopharmaceutical company’s stock after purchasing an additional 439 shares during the period. Bleakley Financial Group LLC’s holdings in Alnylam Pharmaceuticals were worth $609,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Quattro Financial Advisors LLC boosted its stake in shares of Alnylam Pharmaceuticals by 2,517.8% during the 1st quarter. Quattro Financial Advisors LLC now owns 5,000 shares of the biopharmaceutical company’s stock valued at $747,000 after purchasing an additional 4,809 shares in the last quarter. Plato Investment Management Ltd boosted its stake in Alnylam Pharmaceuticals by 2,666.3% during the 1st quarter. Plato Investment Management Ltd now owns 4,509 shares of the biopharmaceutical company’s stock valued at $674,000 after purchasing an additional 4,346 shares during the last quarter. SteelPeak Wealth LLC raised its stake in shares of Alnylam Pharmaceuticals by 147.7% in the first quarter. SteelPeak Wealth LLC now owns 6,860 shares of the biopharmaceutical company’s stock worth $1,025,000 after purchasing an additional 4,090 shares during the last quarter. Diversified Trust Co bought a new position in shares of Alnylam Pharmaceuticals during the second quarter valued at $1,210,000. Finally, Headlands Technologies LLC bought a new position in Alnylam Pharmaceuticals during the 1st quarter valued at about $471,000. 92.97% of the stock is currently owned by institutional investors.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director Dennis A. Ausiello sold 20,250 shares of the company’s stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $262.00, for a total value of $5,305,500.00. Following the completion of the sale, the director now directly owns 136 shares in the company, valued at approximately $35,632. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Alnylam Pharmaceuticals news, Director Dennis A. Ausiello sold 20,250 shares of the stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total transaction of $5,305,500.00. Following the completion of the sale, the director now directly owns 136 shares of the company’s stock, valued at approximately $35,632. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Yvonne Greenstreet sold 15,000 shares of the stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $280.00, for a total value of $4,200,000.00. Following the sale, the chief executive officer now owns 73,441 shares of the company’s stock, valued at approximately $20,563,480. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 50,398 shares of company stock worth $13,595,460 in the last quarter. 1.50% of the stock is owned by company insiders.

Alnylam Pharmaceuticals Trading Down 1.3 %

ALNY opened at $292.01 on Tuesday. The stock has a 50-day moving average of $272.26 and a 200 day moving average of $218.51. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $304.39. The firm has a market cap of $36.94 billion, a P/E ratio of -108.96 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.61. The firm had revenue of $659.83 million during the quarter, compared to analysts’ expectations of $447.22 million. During the same period in the prior year, the company posted ($2.21) EPS. The company’s revenue was up 107.0% compared to the same quarter last year. On average, research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.73 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on ALNY. Wells Fargo & Company upped their price target on shares of Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the company an “equal weight” rating in a research report on Friday, August 2nd. Citigroup upped their price objective on Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. The Goldman Sachs Group upgraded Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their target price for the company from $198.00 to $370.00 in a research report on Friday, August 16th. Needham & Company LLC reaffirmed a “buy” rating and issued a $320.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Thursday, October 10th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the company a “neutral” rating in a research report on Monday, August 26th. Six equities research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $290.86.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.